Market Overview

Illumina to Acquire Verinata Health for $350M


Illumina (NASDAQ: ILMN) today announced that it has signed a
definitive agreement to acquire Verinata Health, Inc., a leading
provider of non-invasive tests for the early identification of fetal
chromosomal abnormalities, for consideration of $350 million plus up to
$100 million in milestone payments through 2015. Upon completion of the
acquisition, Illumina will have access to Verinata's verifi® prenatal
test, the broadest non-invasive prenatal test (NIPT) available today for
high-risk pregnancies, and to the most comprehensive intellectual
property portfolio in the non-invasive prenatal test industry. As
non-invasive prenatal testing is one of the most rapidly growing areas
utilizing next-generation sequencing, Illumina is uniquely positioned to
be at the forefront of providing superior prenatal testing options.

See full press release

Posted-In: News Guidance M&A


Related Articles (ILMN)

View Comments and Join the Discussion!

Partner Center